Biotechnology company Rakuten Medical Inc announced on Wednesday that it has signed a biopharmaceutical contract manufacturing agreement with LOTTE Biologics, a South Korea-based company that operates integrated biologics facilities in the United States and South Korea.
This agreement is intended to strengthen Rakuten Medical's production capabilities for its oncology therapy, Alluminox platform-based photoimmunotherapy.
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical's global clinical development and future commercialisation.
Rakuten Medical's proprietary photoimmunotherapy technology is designed to selectively target cells in solid tumours, by combining cell-targeting moieties, such as antibodies, with light-activatable agents, enabling focal and selective destruction of solid tumour cells upon light exposure. The therapy is approved in Japan for recurrent head and neck cancer.
A global Phase 3 clinical trial is underway in the United States, Taiwan region and Japan, with plans to start treatment in Ukraine and Poland soon. Rakuten Medical also plans to initiate a Phase 1 clinical trial in Japan for other solid tumours beyond head and neck cancer this year.
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial